Published in Patient Care Law Weekly, May 2nd, 2004
Ciphergen and its collaborators reported that different diseases generate unique host responses that can be distinguished by the quantitative detection of disease-specific protein fragments, potentially opening up a novel approach to multi-biomarker diagnostics. Ciphergen has applied for patents on this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Patient Care Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.